Kodiak Sciences has begun enrolling patients in the global Phase 3 ALTO trial to test KSI-501, a bispecific therapy targeting both IL-6 inflammation and VEGF pathways, in diabetic macular edema (DME) patients. The trial aims to show KSI-501's superiority over aflibercept, a current standard treatment, by potentially offering better vision improvement and longer-lasting effects with fewer injections. This study follows promising Phase 2 results suggesting dual inhibition could provide enhanced benefits. Results from this trial could lead to a new, more effective treatment option for DME, a condition causing vision loss due to retinal swelling.
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Fabrinet is set to report strong Q3 2026 earnings with revenue forecasted at about $1.276 billion, a 41% increase year-over-year, driven by demand in Telecom and Data Center sectors. Earnings per share are expected to rise 45% to $3.81, reflecting ro...
US tech companies have sharply increased bond borrowing to fund AI projects, pushing Treasury yields to multi-year highs. This rise in yields makes interest-bearing assets like bonds more attractive compared to Bitcoin, which has fallen 46.1% over th...
HIVE Digital Technologies shares rose 11% after signing a $350 million, five-year GPU cloud services deal with an investment-grade enterprise customer. This contract supports HIVE's goal of $200 million annual recurring revenue in its GPU cloud busin...
In July 2026, three major publicly traded Bitcoin miners—CleanSpark, BitFuFu, and Canaan—reported declines in Bitcoin production even as Bitcoin's price rose from about $58,500 to nearly $63,000. This drop in output is attributed to network difficult...
